第十讲 国际结算中的单据1(国际结算课件)_百度文库
两大类热门资源免费畅读
续费一年阅读会员，立省24元！
文档贡献者贡献于
评价文档：
59页1下载券32页1下载券16页免费62页1下载券27页免费168页1下载券3页免费52页1下载券29页免费80页1下载券
喜欢此文档的还喜欢35页2下载券33页1下载券23页免费32页1下载券59页1下载券
第十讲 国际结算中的单据1(国际结算课件)|国​际​结​算​(​第​二​版​)​(​梁​琦​主​编​)​专​业​课​件
把文档贴到Blog、BBS或个人站等：
普通尺寸(450*500pix)
较大尺寸(630*500pix)
大小：413.50KB
登录百度文库，专享文档复制特权，财富值每天免费拿！
你可能喜欢您好，欢迎来到中国报告大厅！　　
中国首选市场研究报告门户
Current Location： >> English Report >>
LiPlasome Pharma ApS - Product Pipeline Review - 2014
() Font Size：T|T
Description：
　　Global Markets Direct’s, ‘LiPlasome Pharma ApS - Product Pipeline Review -
2014’, provides an overview of the LiPlasome Pharma ApS’s pharmaceutical
research and development focus.
　　This report provides comprehensive information on the current therapeutic
developmental pipeline of LiPlasome Pharma ApS’s, complete with comparative
analysis at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. It also reviews
latest updates, and featured news and press releases, along with special
features on late-stage and discontinued projects.
　　Global Markets Direct’s report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct’s
proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct’s
team. Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the profiles are
updated with the latest set of information. Additionally, processes including
live news & deals tracking, browser based alert-box and clinical trials
registries tracking ensure that the most recent developments are captured on a
real time basis.
　　The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It strengthens
R&D pipelines by identifying new targets and MOAs to produce first-in-class
and best-in-class products.
　　Note*: Certain sections in the report may be removed or altered based on
the availability and relevance of data for the indicated disease.
　　- The report provides brief overview of LiPlasome Pharma ApS including
business description, key information and facts, and its locations and
subsidiaries
　　- The report reviews current pipeline of LiPlasome Pharma ApS’s human
therapeutic division and enlists all their major and minor projects
　　- The report features product description and descriptive mechanism of
action for key pipeline products along with the product’s developmental history
and major milestones
　　- Special feature on out-licensed and partnered product portfolio
　　- The report summarizes all the dormant and discontinued pipeline
　　- Latest company statement
　　- Latest news and deals relating to the LiPlasome Pharma ApS’s pipeline
　　Reasons to buy
　　- Evaluate LiPlasome Pharma ApS’s strategic position with total access to
detailed information on its product pipeline
　　- Assess the growth potential of LiPlasome Pharma ApS in its therapy areas
　　- Identify new drug targets and therapeutic classes in the LiPlasome Pharma
ApS’s R&D portfolio and develop key strategic initiatives to reinforce
pipeline in those areas
　　- Exploit in-licensing opportunities by identifying windows of opportunity
to fill portfolio gaps
　　- Develop strategic initiatives by understanding the focus areas of
LiPlasome Pharma ApS and exploit collaboration and partnership opportunities
　　- Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage
　　- Plan mergers and acquisitions effectively by identifying the most
promising pipeline of LiPlasome Pharma ApS
　　- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to enhance
and expand business potential and scope
　　- Explore the dormant and discontinued projects of LiPlasome Pharma ApS and
identify potential opportunities in those areas
　　- Avoid Intellectual Property Rights related issues
郑重声明：本报告由中国报告大厅出版，报告版权归宇博智业所有。本报告是中国报告大厅的研究与统计成果，报告为有偿提供给购买报告的客户使用。未获得宇博智业书面授权，任何网站或媒体不得转载或引用，否则宇博智业有权依法追究其法律责任。如需订阅研究报告，请直接联系本网站，以便获得全程优质完善服务。
宇博智业机构业务：
宇博智业机构实力： 　　
Catalog');}">Expand>>
LiPlasome Pharma ApS - Product Pipeline Review - 2014
Table of Contents 2
List of Tables 4
List of Figures 4
LiPlasome Pharma ApS Snapshot 5
LiPlasome Pharma ApS Overview 5
Key Information 5
Key Facts 5
LiPlasome Pharma ApS - Research and Development Overview 6
Key Therapeutic Areas 6
LiPlasome Pharma ApS - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
LiPlasome Pharma ApS - Pipeline Products Glance 10
LiPlasome Pharma ApS - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
LiPlasome Pharma ApS - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
LiPlasome Pharma ApS - Drug Profiles 13
cisplatin liposomal 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
doxorubicin liposomal 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
oxaliplatin liposomal 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
bleomycin sulfate liposomal 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
carboplatin liposomal 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
cytarabine liposomal 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
fluorouracil liposomal 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
methotrexate liposomal 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
LiPlasome Pharma ApS - Pipeline Analysis 21
LiPlasome Pharma ApS - Pipeline Products by Target 21
LiPlasome Pharma ApS - Pipeline Products by Route of Administration 22
LiPlasome Pharma ApS - Pipeline Products by Molecule Type 23
LiPlasome Pharma ApS - Pipeline Products by Mechanism of Action 24
LiPlasome Pharma ApS - Recent Pipeline Updates 25
LiPlasome Pharma ApS - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28
List of Tables
LiPlasome Pharma ApS, Key Information 5
LiPlasome Pharma ApS, Key Facts 5
LiPlasome Pharma ApS - Pipeline by Indication, 2014 7
LiPlasome Pharma ApS - Pipeline by Stage of Development, 2014 8
LiPlasome Pharma ApS - Monotherapy Products in Pipeline, 2014 9
LiPlasome Pharma ApS - Phase I, 2014 10
LiPlasome Pharma ApS - Preclinical, 2014 11
LiPlasome Pharma ApS - Discovery, 2014 12
LiPlasome Pharma ApS - Pipeline by Target, 2014 21
LiPlasome Pharma ApS - Pipeline by Route of Administration, 2014 22
LiPlasome Pharma ApS - Pipeline by Molecule Type, 2014 23
LiPlasome Pharma ApS - Pipeline Products by Mechanism of Action, 2014 24
LiPlasome Pharma ApS - Recent Pipeline Updates, 2014 25
List of Figures
LiPlasome Pharma ApS - Pipeline by Top 10 Indication, 2014 7
LiPlasome Pharma ApS - Pipeline by Stage of Development, 2014 8
LiPlasome Pharma ApS - Monotherapy Products in Pipeline, 2014 9
LiPlasome Pharma ApS - Pipeline by Top 10 Target, 2014 21
LiPlasome Pharma ApS - Pipeline by Top 10 Route of Administration, 2014 22
LiPlasome Pharma ApS - Pipeline by Top 10 Molecule Type, 2014 23
LiPlasome Pharma ApS - Pipeline Products by Top 10 Mechanism of Action, 2014 24
<div class="viewall showfull" style="cursor: " onclick="if($$('div.bgcon').getStyle('height')=='900px') {$$('div.bgcon').setStyle('height', 'auto');$$('.showfull').set('html','<>');}">Expand>>
Previous：Next：
中国报告大厅简介
中国报告大厅(/)成立于2002年10月，是由宇博智业机构(简称：宇博智业) 开通并运营的一家大型专业化市场研究网站，提供针对企业用户的各类信息，如深度研究报告、市场调查、统计数据等。
为了满足企业对原始数据的需求，也为了能给企业提供更为全面和客观的研究报告，中国报告大厅与国内各大数据源（包括政府机构、行业协会、图书馆、信息中心等权威机构）建立起战略合作关系。
经过多年的努力，中国报告大厅与国内100多家最优质研究公司建立良好的合作关系，推出超过50000份有价值的行业研究报告，中国报告大厅目标是打造一个真正的一站式服务的多用户报告平台。中国报告大厅汇聚全国各大市场研究信息生产商的研究成果，正是依托独有的资源优势，为客户提供最准确、最及时、最权威、最专业的市场研究报告。
Related Report
Newest Report
Related Category
线下购买流程
1. 双方洽谈 明确需求
电话或网络确定购买细节
2. 签订服务合同
签订研究报告购买合同
3. 支付款项
支付报告购买款项
4. 购买成功
交付报告并售后服务一年
A. 电话订购：400-817-8000
B. 邮件订购：
C. 网上订购：
D. 直接到我公司上门购买：
温馨提示：
1、购买报告请认准“中国报告大厅"网站，公司从未通过第三方代理，请来电购买。
2、中国报告大厅欢迎广大客户上门洽谈购买。
我们的优势
我们的优势丰富的信息资源
　宇博智业机构依托国家发展改革委和国家信息中心系统丰富的数据资源，以及国内其他各大数据源（包括行业协会、图书馆、相关研究机构等）建立的战略合作关系，建成了独具特色和覆盖全面的产业监测体系。
专业的研究团队
　公司人员拥有不同背景和资历的研究人员，每份报告都由多年从事相关行业的资深研究员撰写，他们长期专门从事行业研究，掌握着大量的第一手资料；同时，为保证研究成果的前瞻性，我们与国内众多研究机构和专家有着密切的合作关系。
　①宇博智业机构创立于2002年，中国最早的市场研究机构之一；②公司拥有强大的调研团队，能为报告的撰写提供可靠的一手资料。③研究人员根据对中国文化的深刻理解，实现国际领先研究方法与本土实践经验巧妙结合。
售前售后服务
　公司拥有一批专业的业务人员，将根据您的需求，为您提供详细的解答并提供相符合的报告目录；报告售出后，我们的研究人员将会为您提供全程的后续修改及补充服务。
赠送增值服务
　购买我们研究报告可获赠报告大厅数据中心会员资格，全方面了解行业动态。
Industry Information
Free Report
Data Center
& 2015 中国报告大厅()，首选市场研究报告门户，提供海量的行业报告及市场前景研究报告。
服务热线：北京：010-- 传真：010- E-mail：
福建： &&&&传真：
中文域名：.com
中国报告大厅—宇博智业市场研究中心主办，旗下网站
京ICP备号-2&&京公网安备80